Clinical Trials for Non-Small Cell Lung Cancer

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with locally advanced or metastatic pancreatic, lung, breast, and colorectal cancers who have progressed after standard treatments and exhibit tumor uptake of [68Ga]Ga-NNS309. It evaluates the safety and preliminary activity of the investigational radioligand [177Lu]Lu-NNS309, which targets specific tumor markers, though its exact mechanism of action is undisclosed.

ClinicalTrials.gov ID: NCT06562192

An Open-label, Phase I, Dose Escalation, Expansion Study of MGY825 in Adult Patients With Advanced Non-small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates MGY825, a novel targeted therapy aimed at inhibiting mutant NFE2L2, KEAP1, and CUL3 proteins, in adult patients with advanced NSCLC, particularly those with tumors harboring mutations in these genes, though it also includes one cohort of patients irrespective of mutation status.

ClinicalTrials.gov ID: NCT05275868

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy in Patients with Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced or metastatic solid tumors, such as melanoma and non-small cell lung cancer, who have had prior therapies, evaluating the safety and efficacy of Alintegimod, an integrin-targeting agent, combined with ipilimumab and nivolumab.

ClinicalTrials.gov ID: NCT06362369

Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered As Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors, including those with mutations such as HRAS, KRAS, and NRAS, testing KO-2806, a farnesyltransferase inhibitor aimed at inhibiting RAS protein modifications and mTOR signaling, administered alone or with other agents like KRAS inhibitors and tyrosine kinase inhibitors.

ClinicalTrials.gov ID: NCT06026410

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced solid tumors, such as ovarian and non-small cell lung cancers, expressing folate receptor alpha, and evaluates the investigational antibody-drug conjugate LY4170156, which targets these cells using a unique exatecan payload for potential enhanced efficacy.

ClinicalTrials.gov ID: NCT06400472

Pilot Study of Ruxolitinib in the Treatment of Cancer Cachexia

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the use of Ruxolitinib, a JAK 1/2 inhibitor that targets the JAK/STAT signaling pathway, in adult patients with stage IV non-small cell lung cancer experiencing cancer cachexia to assess its toxicity profile and therapeutic effects on cachexia symptoms. Participants are newly diagnosed, have demonstrated weight loss, and have not received prior targeted cancer therapy.

ClinicalTrials.gov ID: NCT04906746

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced, And/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates NT-112, an autologous engineered T-cell therapy targeting KRAS G12D mutations in HLA-C*08:02-positive adults with advanced solid tumors, including non-small cell lung, colorectal, pancreatic, and endometrial cancer, following lymphodepletion and IL-2 treatment.

ClinicalTrials.gov ID: NCT06218914

An Open-Label, Phase 1b/2a Study of SLC-391, an AXL Inhibitor, in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced or metastatic non-small cell lung cancer (NSCLC), exploring the combination of SLC-391, a selective AXL receptor tyrosine kinase inhibitor, with pembrolizumab, a PD-1 checkpoint inhibitor, in both treatment-naïve patients and those with progression after prior therapies.

ClinicalTrials.gov ID: NCT05860296

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates AZD9592, a bispecific antibody-drug conjugate targeting EGFR and cMET receptors, in adult patients with advanced solid tumors, including metastatic or recurrent NSCLC, head and neck squamous cell carcinoma, and colorectal cancer, as a monotherapy and in combination with agents like Osimertinib and a 5-FU, Bevacizumab, and Leucovorin regimen.

ClinicalTrials.gov ID: NCT05647122

A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF9001 as a Monotherapy and in Combination Therapies in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates the investigational drug DF9001, a multi-specific immunotherapy targeting EGFR signaling and immune cell activation, administered alone or with pembrolizumab, in adults with advanced solid tumors expressing EGFR, including NSCLC, HNSCC, and RCC, following disease progression after prior therapies.

ClinicalTrials.gov ID: NCT05597839